

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/08, 47/26, 31/70	A1	(11) International Publication Number: WO 93/02663 (43) International Publication Date: 18 February 1993 (18.02.93)
(21) International Application Number: PCT/GB92/01407 (22) International Filing Date: 29 July 1992 (29.07.92) (30) Priority data: 91/09651 30 July 1991 (30.07.91) FR (71) Applicants (for all designated States except US): LABORATOIRES MERCK SHARP & DOHME-CHIBRET [FR/FR]; 3, avenue Hoche, F-75008 Paris (FR). THOMPSON, John [GB/GB]; M.S.D. Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). (72) Inventor; and (75) Inventor/Applicant (for US only) : ROZIER, Annouk [FR/FR]; Domaine de la Pegoire, F-63360 St. Beauzire (FR).		(74) Agent: THOMPSON, John; Merck & Co., Inc., European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). (81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE). Published <i>With international search report.</i>
(54) Title: OPTHALMIC COMPOSITIONS BASED ON POLYHYDRIC ALCOHOLS (57) Abstract The present invention relates to an ophthalmic composition comprising at least one active principle and at least one ophthalmically acceptable osmotic agent having antimicrobial activity, typically xylitol; and to a process for the preparation thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain			US	United States of America

- 1 -

OPHTHALMIC COMPOSITIONS BASED ON POLYHYDRIC ALCOHOLS

5 The present invention relates to ophthalmic compositions, and concerns more especially the preservatives contained in ophthalmic compositions.

 Ophthalmic compositions generally consist of at least one active principle, and an excipient containing
10 at least one inorganic or organic osmotic agent which imparts to the preparation an osmotic pressure corresponding to that of the lachrymal fluid. The osmotic pressure of the lachrymal fluid is equivalent to that of a 0.93% NaCl solution.

15 An inorganic osmotic agent commonly employed in ophthalmic preparations is sodium chloride. Examples of organic osmotic agents commonly employed in ophthalmic formulations include hydrogenated hexoses such as mannitol and sorbitol.

20 Ophthalmic compositions must also be sterile when used. However, whilst sodium chloride remains neutral with respect to bacterial growth, the hydrogenated hexoses generally employed as excipients tend to promote microorganism growth.

25 It is hence necessary either to prepare sterile single doses which are discarded after each use, thereby increasing production costs, or to incorporate into the ophthalmic composition preservatives which are microorganism growth inhibitors.

30 The preservatives generally employed have many drawbacks. In particular, they might exhibit some degree of toxicity through the corneal epithelium, or else they might induce allergic reactions if used at excessively high concentrations. Alternatively, if used at too low

- 2 -

concentrations, certain preservatives may not be sufficiently active against some microorganisms.

We have now found unexpectedly that certain acceptable osmotic agents, namely those having antimicrobial activity, may advantageously replace, partially or wholly, the osmotic agents commonly used in ophthalmic compositions, thereby enabling the use of possibly toxic or irritant preservatives to be decreased or even excluded and the spectrum of microorganisms eliminated to be broadened. A class of acceptable osmotic agents of particular value in this regard includes the hydrogenated pentose derivatives such as xylitol and related compounds of the xylitol type.

The present invention accordingly relates to an ophthalmic composition comprising at least one active principle and an excipient, characterised in that the excipient contains at least one ophthalmically acceptable osmotic agent having antimicrobial activity, preferably a hydrogenated pentose derivative such as xylitol.

By the expression "ophthalmically acceptable osmotic agent" is meant a compound which imparts to an ophthalmic composition an osmotic pressure corresponding to that of a NaCl solution which is acceptable to the eye; in other words, a composition which neither irritates nor adversely affects the parts of the eye with which it will come into contact. By way of guidance, it is to be noted that the limits imposed by the USP for acceptable ophthalmic solutions are from 0.6 to 2% by weight of NaCl.

The hydrogenated pentose derivatives, such as xylitol or related compounds of the xylitol type, may be employed alone or mixed with at least one other osmotic agent suitably selected from sodium chloride, mannitol, sorbitol and mixtures thereof.

- 3 -

By the expression "agent having antimicrobial activity" is meant a compound which inhibits microorganism growth or destroys microorganisms, such microorganisms typically including bacteria and fungi.

5 The composition according to the invention may also advantageously incorporate at least one standard preservative. Examples of suitable preservatives include benzalkonium chloride, thimerosal, benzododecinium
10 bromide, parabens and their sodium salts, chlorobutanol, aromatic alcohols, chlorhexidine, and mercury
15 derivatives, as well as other preservatives well known to those skilled in the art, and mixtures thereof.

 The ophthalmic composition according to the present invention may suitably take the form of a
15 solution, a gel, a suspension or an emulsion, preferably an aqueous solution. The ophthalmically acceptable osmotic agent having antimicrobial activity such as a
20 hydrogenated pentose derivative, e.g. xylitol, is employed therein as a replacement for the osmotic agents
25 commonly used in known preparations of the prior art.

 The ophthalmically acceptable osmotic agent having antimicrobial activity is incorporated into the preparations of the present invention such that these preparations display a cryoscopic lowering property of
25 between -0.34°C and -1.16°C . An ophthalmic composition in accordance with the present invention capable of
30 showing such a cryoscopic lowering typically comprises from 0.1 to 9%, preferably from 2.0 to 9%, by weight of xylitol.

 It is possible to use in the composition according to the invention a wide variety of active principles. They may typically be selected from the following pharmaceutical compounds:

- 4 -

- antibacterial substances such as beta-lactam antibiotics, for example cefoxitin, n-formamidoylthienamycin and other thienamycin derivatives, tetracyclines, chloramphenicol, neomycin, carbenicillin, colistin, penicillin G, polymyxin B, vancomycin, cefazolin, cephaloridine, chibrorifamycin, gramicidin, bacitracin and sulfonamides;
- aminoglycoside antibiotics such as gentamycin, kanamycin, amikacin, sisomicin and tobramycin;
- nalidixic acid and its analogues such as norfloxacin and the antimicrobial combination fluoroalanine/pentizidone, nitrofurazones and analogues thereof;
- antihistamines and decongestants such as pyrilamine, chlorpheniramine, tetrahydrazoline, antazoline and analogues thereof;
- anti-inflammatories such as cortisone, hydrocortisone, hydrocortisone acetate, betamethasone, dexamethasone, dexamethasone sodium phosphate, prednisone, methylprednisolone, medrysone, fluorometholone, prednisolone, prednisolone sodium phosphate, triamcinolone, indomethacin, sulindac, its salts and corresponding sulphides, and analogues thereof;
- miotics and anticholinergics such as echothiopate, pilocarpine, physostigmine salicylate, diisopropyl-fluorophosphate, epinephrine, dipivaloyl epinephrine, neostigmine, echothiopate iodide, demecarium bromide, carbamoyl choline chloride, methacholine, bethanechol and analogues thereof;
- mydriatics such as atropine, homatropine, scopolamine, hydroxyamphetamine, ephedrine, cocaine, tropicamide, phenylephrine, cyclopentolate, oxyphenonium, eucatropine and analogues thereof;
- other drugs used in the treatment of eye conditions and lesions, such as antiglaucoma drugs, for example timolol,

- 5 -

- R-timolol, and a combination of timolol or R-timolol with pilocarpine, as well as many other adrenergic agonists and/or antagonists; epinephrine, and epinephrine complexes or prodrugs, and dipivefrine derivatives and
- 5 hyperosmotic agents such as glycerol, mannitol and urea; and carbonic anhydrase inhibitors such as acetazolamide, dichlorphenamide, 2-(p-hydroxyphenyl)thio-5-thiophenesulphonamide, 6-pivaloyloxy-2-benzothiazolesulphonamide, MK-927 and MK-417;
- 10 - antiparasitic compounds and/or antiprotozoal compounds such as ivermectin, pyrimethamine, trisulphapyrimidine, clindamycin and corticosteroid preparations;
- compounds having antiviral activity such as acyclovir, 5-iodo-2'-deoxyuridine (IDU), adenosine arabinoside (Ara-
- 15 A), trifluorothymidine, and interferon and interferon-inducing agents such as polyI.polyC;
- antifungal agents such as amphotericin B, nystatin, flucytosine, natamycin and miconazole;
- anaesthetic agents such as etidocaine, cocaine,
- 20 benoxinate, dibucaine hydrochloride, dyclonine hydrochloride, naepaine, phenacaine hydrochloride, piperocaine, proparacaine hydrochloride, tetracaine hydrochloride, hexylcaine, bupivacaine, lidocaine, mepivacaine and prilocaine;
- 25 - ophthalmic diagnostic agents such as:
- a) those which are used for examining the retina, such as fluorescein sodium;
- b) those which are used for examining the conjunctiva, cornea and lachrymal apparatus, such as
- 30 fluorescein and rose bengal; and
- c) those which are used for examining abnormal responses of the pupil, such as methacholine, cocaine, adrenaline, atropine, hydroxyamphetamine and pilocarpine;

- 6 -

- ophthalmic agents used as surgical aids, such as alpha-chymotrypsin and hyaluronidase;
- chelating agents such as ethylenediaminetetraacetic acid (ETDA) and deferoxamine;
- 5 - immunosuppressants and antimetabolites such as methotrexate, cyclophosphamide, 6-mercaptopurine and azathioprine; and antibiotic/anti-inflammatory combinations such as the combination neomycin sulphate/dexamethasone sodium phosphate, and combinations
- 10 concomitantly treating glaucoma, for example a timolol maleate/aceclidine combination.

The active principle may typically be present in the ophthalmic composition according to the invention in an amount of from about 0.001% to about 5% by weight, suitably from 0.1% to 2% by weight.

Finally, gelling or viscosifying agents may be advantageously incorporated into the preparations of the present invention. Such agents include in particular polysaccharides such as gellan gum, especially the product sold by the Kelco company under the trade name Gelrite; carboxylic polymers such as those designated by the trade mark Carbopol; cellulose derivatives, for example carboxymethylcellulose or hydroxyethylcellulose (HEC); polyvinyl alcohols (PVA); polyvinylpyrrolidone (PVP); and mixtures thereof.

It will be appreciated that, in practice, certain gelling or viscosifying agents have a tendency to be incompatible with certain mineral osmotic agents. For example, Gelrite^R interacts rapidly with sodium chloride to form a gel, and Carbopol^R gives an unwanted precipitate in the presence of sodium chloride. Combinations of gelling or viscosifying agents and mineral osmotic agents which interact undesirably in this way are consequently best avoided. The person skilled in

- 7 -

the art will either be already aware of which combinations to avoid, or be capable of ascertaining such incompatible combinations on the basis of simple trial and error.

5 The present invention also concerns a process for preparing the above-described composition, characterised in that an ophthalmically acceptable osmotic agent having antimicrobial activity is mixed with the other components constituting the composition under
10 agitation in an aqueous solution and then sterilized.

 Table I below describes the composition of two dilute ophthalmic solutions, one being rendered isotonic with xylitol according to the present invention (Example 1), the other being rendered isotonic in a conventional
15 manner with mannitol (Example 2). The proportions are given in percentages by weight relative to the total weight of the composition.

 Both solutions are prepared in an identical way by dissolving the different compounds in water under
20 agitation, the gelling or viscosifying agent being incorporated last. After dissolving all the components, the ophthalmic solutions are sterilized in an autoclave.

 Both compositions have an identical concentration of preservative (0.01% benzododecinium
25 bromide), and differ only in the tonicity agent employed.

30

- 8 -

TABLE 1

	<u>EXAMPLE 1</u>	<u>EXAMPLE 2</u>
Timolol maleate	0.684	0.684
5 Xylitol	3.20	0
Mannitol	0	4.05
Tromethamine	0.182	0.182
Benzododecinium		
bromide, anhydrous	0.01	0.01
10 Gelrite ^R , anhydrous	0.60	0.60
Water for injection qs		100
Freezing-point.		
depression	-0.51°C	-0.54°C

15

A simplified test of efficacy of preservatives according to the British Pharmacopoeia (1988, Appendix XVI C) was performed for the two compositions, with respect to Aspergillus niger.

20

The results of these comparative tests, as displayed in Table II below, show clearly the major advantage of incorporating xylitol into a composition of this type.

25

TABLE II

Aspergillus niger count according to the B.P., 1988

	<u>EXAMPLE 1</u>	<u>EXAMPLE 2</u>
30 Inoculum	9.00×10^6	1.80×10^7
Time zero	8.00×10^4	1.60×10^5
7 Days	40	6.50×10^3
14 Days	1	6.00×10^3

- 9 -

CLAIMS:

1. An ophthalmic composition comprising at least one active principle and an excipient, characterised in that the excipient contains at least one ophthalmically acceptable osmotic agent having antimicrobial activity.
2. A composition as claimed in claim 1, characterised in that the ophthalmically acceptable osmotic agent having antimicrobial activity is a hydrogenated pentose derivative.
3. A composition as claimed in claim 2, characterised in that the ophthalmically acceptable osmotic agent having antimicrobial activity is xylitol.
4. A composition as claimed in any one of the preceding claims, characterised in that it further contains at least one other osmotic agent selected from sodium chloride, mannitol, sorbitol and mixtures thereof.
5. A composition as claimed in any one of the preceding claims, characterised in that it further contains at least one standard preservative.
6. A composition as claimed in any one of the preceding claims, characterised in that it comprises from 0.1 to 9% by weight of xylitol.
7. A composition as claimed in any one of the preceding claims, characterised in that it further comprises a gelling or viscosifying agent.

- 10 -

8. A composition as claimed in claim 7,
characterised in that the gelling or viscosifying agent
is selected from polysaccharides, carboxylic polymers,
5 cellulose derivatives, and mixtures thereof.


9. A composition as claimed in any one of the
preceding claims, characterised in that the active
principle is selected from antiglaucoma drugs,
10 antibiotics and compounds having antiviral activity.

10. A process for preparing an ophthalmic
composition as claimed in any one of the preceding
claims, characterised in that an ophthalmically
15 acceptable osmotic agent having antimicrobial activity is
mixed with the other components constituting the
composition under agitation in an aqueous solution and
then sterilized.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 92/01407

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl.5 A 61 K 9/08 A 61 K 47/26 A 61 K 31/70		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl.5	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ^o	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	GB,A,2199745 (HOKURIKU) 20 July 1988, see claims; page 3, lines 18-20,30; page 4, lines 15-24 ---	1,3,5-6,9-10
X	Database: WPIL, accession no. 88-016591 (03), Derwent Publications Ltd, London, GB, & JP,A,62277323 (SANKYO K.K.) 2 December 1987, see abstract ---	1-3,5-6,9-10
X	EP,A,0080879 (SUNSTAR) 8 June 1983, see claims 1-2,12; page 2, lines 10-15; page 3, lines 15-19; page 6, lines 6-9,15 -----	1-4,7-10
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>^o Special categories of cited documents : ¹⁰</p> <p>^{"A"} document defining the general state of the art which is not considered to be of particular relevance</p> <p>^{"E"} earlier document but published on or after the international filing date</p> <p>^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>^{"O"} document referring to an oral disclosure, use, exhibition or other means</p> <p>^{"P"} document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>^{"X"} document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>^{"Y"} document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>^{"&"} document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
16-10-1992		20. 11. 92
International Searching Authority		Signature of Authorized Officer ⁷
EUROPEAN PATENT OFFICE		

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9201407
SA 63139

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 06/11/92
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A- 2199745	20-07-88	JP-A- 63174930	19-07-88
		CH-A- 676549	15-02-91
		DE-A, C 3715918	28-07-88
		FR-A- 2609394	15-07-88
		SE-A- 8701961	15-07-88
		US-A- 4780465	25-10-88
EP-A- 0080879	08-06-83	JP-A- 58167520	03-10-83
		JP-C- 1452214	25-07-88
		JP-A- 58092619	02-06-83
		JP-B- 62060370	16-12-87
		JP-B- 3008323	05-02-91
		JP-A- 58092620	02-06-83
		JP-A- 58092621	02-06-83
		JP-A- 58092622	02-06-83
		US-A- 4675184	23-06-87

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82